FDA last inspected it on March 12, 2026 and issued a Form 483 with 9 observations.
These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.
What does FDA’s record show, in brief?
| Facility | BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy |
| Location | Temple Terrace, Florida |
| Type | 503B outsourcing facility |
| Registered since | June 4, 2019 |
| Latest registration | February 5, 2026 |
| Last FDA inspection | March 12, 2026 |
| Inspection dates | 2/17/2026 to 3/12/2026 |
| Form 483 | Issued, 9 observations |
| FDA action after the inspection | FMD-145 Letter Issued 9/18/202 |
| Compounds sterile drugs from bulk | No |
| FDA warning letters on GLP-1 drugs | 0 |
What did FDA’s investigators observe?
The Form 483 from the inspection of 3/12/2026 lists 9 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2
| What the observation is about | Observations |
|---|---|
| Sterility and aseptic processing | 4 |
| Labeling and records | 2 |
| Environmental and personnel monitoring | 2 |
| Cleaning and disinfection | 1 |
FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.
Has this facility recalled any drugs?
FDA’s enforcement reports list 3 recalled products from this facility, from July 30, 2021 to December 1, 2022: 1 in Class I, 1 in Class II, 1 in Class III. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3
| Started | Class | Product | Reason |
|---|---|---|---|
| 2022-12-01 | I | Iohexol (300 mg Iodine/mL) | Labeling: Label Error on Declared Strength: syringes mislabeled as 300 mg iodine/mL contained product 350 mg iodine/mL |
| 2022-02-14 | III | Norepinephrine bitartrate 16 mg in 250 mL NaCl 0.9% | Subpotent drug |
| 2021-07-30 | II | Succinylcholine Chloride 100 mg/5 mL (20 mg/mL) | Lack of sterility assurance |
Is the pharmacy behind my prescription on FDA’s list?
Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.
Where are the registered outsourcing facilities?
16 of the 100 facilities on FDA’s list are in Florida. The chart counts them by state; choose a view to see which ones FDA has inspected.
Which other facilities are in the same state?
What does it mean that a pharmacy is a 503B outsourcing facility?
An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1
A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.
Sources
- FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
- FDA. Form FDA 483, inspection of BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy, 2/17/2026 to 3/12/2026. fda.gov
- FDA. Drug recall enforcement reports for BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy, read through openFDA on November 20, 2026. open.fda.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider